
Please try another search
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company’s lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson’s disease with or without a GBA1 mutation. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher’s disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Name | Age | Since | Title |
---|---|---|---|
Gwen A. Melincoff | 73 | 2021 | Independent Director |
Jeffrey Lucero Riley | 62 | 2019 | Independent Director |
Wilma D.J. Van Van de Berg | - | 2025 | Member of Clinical Advisory Board |
Roy Alcalay | - | 2025 | Member of Clinical Advisory Board |
Hans Peter Hasler | 69 | 2021 | Independent Director |
Samuel E. Broder | 80 | - | Member of Clinical Advisory Board |
Claude Nicaise | 72 | 2021 | Independent Director |
Eric I. Richman | 64 | 2020 | Director |
Dov A. Goldstein | 58 | 2021 | Independent Director |
Karl Kieburtz | - | 2025 | Member of Clinical Advisory Board |
Khalid Islam | 70 | 2017 | Chairman & Founder |
Gene Mack | - | 2024 | President, CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review